ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / IRMD
SGP (43) AORT (41) PRCT (40) SIBN (53) ⌘ Pro Terminal →

iRadimed Corporation (IRMD) — RQD Stock Rating Cockpit

$76.68 -10.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $75.08

iRadimed Corporation (IRMD) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY) →
ROARABLE C- • HOLD / WATCH Cap $1.10B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IRMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, iRadimed Corporation (NASDAQ: IRMD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $76.68 (-10.57% 1D, market cap $1.10B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, IRMD ranks #186 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IRMD compare to SGP and AORT in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), IRMD carries a Roarable C- (59/100 RQD), trailing P/E of 48.8x, gross margin of 76.7%, and ROIC of 37.7%. By comparison, SGP (SpyGlass Pharma Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $1.09B) and AORT (Artivion Inc.) posts a D- grade (41/100 RQD, P/E 117.0x, ROIC 4.5%, cap $1.14B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IRMD?
▼

Per IRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001325618), iRadimed Corporation generated $83.8M in revenue (+14.4% YoY), $22.5M in net income, and $17.2M in free cash flow against $108.8M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (77% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $75.08 (-2.09%)🧬 Disciplined Float (-0.32% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 20.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C-
025507510059
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk D+
Cash (16)Whales (7)SEC (14)Macro (9)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE+0.5% Base Target
$113 Bull$77 Base$60 Bear
📬 FREE IRMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IRMD)Realized 20D OHLCV Swing Band: ±5.6%
Deterministic 5-Pillar Attribution (59/100 Composite)
🔍 WHY IRMD SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 20.5% FCF Margin ($17.2M FCF) & 76.7% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
67
Grade B-$89.47-2% Next Q
Q2 (-2Q)
64
Grade C+$87.65-3.4% Next Q
Q3 (-1Q)
62
Grade C+$84.63-9.4% Next Q
Current
59
Grade C-$76.68+0.2% Hist 90D α
Trajectory: B- (67) → C- (59)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the IRMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, IRMD faces multiple-compression risk if 48.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Priced at 49x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($85.62) or 200D SMA ($92.46) invalidates the momentum regime and cuts Target Base ($77.03) toward Bear Floor ($60.08).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IRMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IRMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 59%NO 41%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
50.130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
8 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $76$76.68H: $108
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (77% profit margin and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on IRMD

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (80)

37.7% ROIC with 76.7% gross margin and 1.57% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (70)

Altman-Z 4.20 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (48)

20/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like IRMD
  • ✓Strong cash generator (77% profit margin)—profits are backed by real money, not accounting tricks.
Bear Case: What Could Go Wrong
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Priced at 49x earnings—high expectations leave less room for a lukewarm quarter.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (IRMD Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IRMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.70%🛡️ HOLDING TREND SUPPORT
2026-11-02O $83.93H $85.74L $76.68C $76.68VOL 92.6K
RES: $91.69SUP: $76.11SMA50: $85.62SMA200: $92.46
$104.9$97.13$89.40$81.68$73.95RES $91.69SUP $76.11$76.682026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IRMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IRMD Butterfly Map → + Track IRMD →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
35.7%/yr Implied 5Y Growth

vs. +14.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IRMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IRMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IRMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IRMD)

Health Care Rank #186 of 1016 ⚔️ SGP vs IRMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IRMD vs. SGP, AORT, PRCT, SIBN)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, iRadimed Corporation (IRMD) ranks #186 by composite RQD confidence (59/100, grade C-) and #351 by equity capitalization ($1.10B). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IRMD ACTIVE
iRadimed Corporation
C- 59/100 48.8x 76.7% 37.7% -10.57% $1.10B Benchmark Subject
SGP
SpyGlass Pharma Inc.
D- 43/100 — — -35.0% -0.83% $1.09B /sgp-vs-irmd →
AORT
Artivion Inc.
D- 41/100 117.0x 64.4% 4.5% -3.67% $1.14B /aort-vs-irmd →
PRCT
PROCEPT BioRobotics Corporation
D- 40/100 — 63.7% -35.0% -5.42% $1.16B /prct-vs-irmd →
SIBN
SI-BONE Inc.
D+ 53/100 — 79.6% -10.3% -5.27% $1.00B /sibn-vs-irmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001325618

In its most recent audited fiscal period (FY2025, filed 2025-12-31), iRadimed Corporation (IRMD) reported GAAP revenue of $83.8M (+14.4% vs. FY2024 revenue of $73.2M , and +27.8% cumulative change since FY2023) , GAAP net income of $22.5M, operating cash flow of $24.9M, and free cash flow of $17.2M (-2.5% YoY). On the balance sheet, IRMD closed FY2025 with $108.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $83.8M $22.5M $24.9M $17.2M $108.8M —
FY2024 (FY) 2024-12-31 $73.2M $19.2M $25.6M $17.6M $98.3M —
FY2023 (FY) 2023-12-31 $65.6M $17.2M $13.5M $13.5M — —

3. IRMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, iRadimed Corporation (NASDAQ: IRMD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $76.68 (-10.57% 1D, market cap $1.10B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, IRMD ranks #186 in composite RQD confidence.

How does IRMD compare to SGP and AORT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), IRMD carries a Roarable C- (59/100 RQD), trailing P/E of 48.8x, gross margin of 76.7%, and ROIC of 37.7%. By comparison, SGP (SpyGlass Pharma Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $1.09B) and AORT (Artivion Inc.) posts a D- grade (41/100 RQD, P/E 117.0x, ROIC 4.5%, cap $1.14B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IRMD?

Per IRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001325618), iRadimed Corporation generated $83.8M in revenue (+14.4% YoY), $22.5M in net income, and $17.2M in free cash flow against $108.8M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (77% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IRMD trading relative to its 50-day, 200-day, and 52-week technical levels?

IRMD last traded at $76.68 (-10.57% on volume of 218,060 shares), positioning the stock -10.44% below its 50-day simple moving average ($85.62) and -17.07% below its 200-day simple moving average ($92.46). Across its 52-week range of $76.35 to $107.90, IRMD sits at the 1.0% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of ±5.6% ($72.39 to $80.97).

IRMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell IRMD stock right now?

iRadimed Corporation (IRMD) currently earns a Roarable Rating of C- (Hold — HOLD) with 59/100 RQD Confidence. Solid 77% profit margin (38% return on capital), mixed timing at 49x P/E—hold if owned, no rush to chase.

What is IRMD's 12-month price target and RQD AI Jury consensus?

IRMD's 12-month base price target is $77.03 (range $60.08 to $113.3), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: IRMD RQD Cockpit IRMD 12M Forecast IRMD Earnings & Move IRMD Dividends & DRIP IRMD Insiders & 13F IRMD Whale Options IRMD Profit Sankey IRMD News & Why
ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

IRMD — iRadimed Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:30:45Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, IRMD scores 59 out of 100, a letter grade of C-, labeled "Roarable Hold — Cautious Neutral." The five pillars are: Fundamental Cash Engine 16/20 (ROIC 37.7%; FCF yield 1.57%); Whale 13F Flow 7/20 (institutional accumulation and options positioning); Insider Conviction 13/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 9/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 14/20 (Altman Z 2.5; Piotroski F 8/9; Debt/Equity 0.5).

For a prospective investor, the strongest pillar is the cash engine, supported by a 37.7% ROIC and a 26.8% net margin per the market data. The weakest pillar is macro regime fit (9/20) and institutional flow (7/20), which signal that the stock is not currently benefiting from a clear sector tailwind or strong institutional accumulation. The valuation tradeoff is significant: a P/E (TTM) of 48.8 and an EV/EBITDA of 31.9 against a 1.57% FCF yield mean that the price already embeds substantial expectations for future growth, leaving limited margin for error if earnings disappoint. The balance sheet pillar is solid, but the rating's overall verdict reflects that quality is priced in and near-term catalysts are mixed. This is an educational summary of the rating framework, not personalized financial advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
85.74$1.1B48.84131.91.761.37%1.0$76.35 - $107.937.7%

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$83.8M$26.1M$22.5MN/A$17.2M$51.2MN/A
FY 2024$73.2M$22.0M$19.2MN/A$17.6M$52.2MN/A
FY 2023$65.6M$20.0M$17.2MN/A$13.5MN/AN/A

Per the SEC financials, revenue grew from $65.6M (FY 2023) to $73.2M (FY 2024) to $83.8M (FY 2025), and net income rose from $17.2M to $22.5M over the same span. Per the market data, net margin is 26.8% and ROIC is 37.7%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 8/9, both per the Roarable RQD rating; the Debt/Equity ratio is 0.5. FCF declined slightly from $17.6M in FY 2024 to $17.2M in FY 2025. Cash was $51.2M at FY 2025 versus $52.2M at FY 2024.

Recent Catalysts & News Wire Analysis

Per the recent news feed, headlines reference a Q3 earnings call, Q3 revenue rising 14% to $24.2 million (Quiver Quantitative), and an expected Q4 revenue range of $25.0M – $26.5M (marketscreener.com). A Simply Wall St piece references a price of US$83.95. BlackRock is reported to hold voting power over 614,615 IRMD shares alongside a passive stake (Stock Titan). All six feed items carry a YELLOW light and MARKET WIRE impact label. Risk watch items and proprietary signals: Not available in source data beyond the headlines above; the Butterfly Supply-Chain Graph lists no proprietary signals.

Analyst View & Smart Money Ownership

Analyst consensus, price targets, and holder detail are not available in the source data (analyst data and holders both NONE). Per the news feed, BlackRock is reported to hold voting power over 614,615 shares alongside a passive stake. No SEC Form 4 insider or Congressional trade detail is provided beyond the RQD insider pillar score of 13/20.

Open Questions

  • What are the specific product lines, customer concentration, and revenue drivers behind the 14% Q3 revenue growth?
  • What are the reported EPS, total debt, and FY 2023 cash balances, which are currently N/A in the financials?
  • What analyst consensus rating and price targets apply, given that analyst coverage data is absent?
  • What insider transactions underlie the 13/20 insider conviction pillar and the Congressional PTR cluster flow?
  • What drives the expected Q4 revenue range of $25.0M – $26.5M relative to prior-year quarters, and what risks could move it?

IRMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for iRadimed Corporation (IRMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IRMD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IRMD Bull vs. Bear Conversation Board — What's Your Call at $76.68?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IRMD 🐻 50% BEARISH CONVICTION
1. Pick Your Side on IRMD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $92.60 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is IRMD (C- • RQD 59/100) a Buy at $85.74?

Welcome to the IRMD (iRadimed Corporation) Roar Pit. Current RQD Composite is 59/100 (Roarable Hold — Cautious Neutral) in Medical/Dental Instruments. Bulls point to capital efficiency (37.7% ROIC), while bears focus on valuation multiple compression (48.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $66.02 (-23.0%)
Spot @ $85.74

Pump the brakes on IRMD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on IRMD, but look at what you are paying: 48.8x trailing P/E with 76.7% gross margins. Unless iRadimed Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $108.03 (+26.0%)
Spot @ $85.74

IRMD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on IRMD, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $85.74 (52-wk range $76.35 - $107.90), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%